# Phase 1 → Phase 2: independent research-quality feedback request

> Cross-phase request for the **Phase 1 Chat coordinator** to inform **Phase 2 iteration 2**. This is advisory research/scientific assessment, not a Blue implementation assignment or an amendment to the Phase 1 numbered handoffs.
>
> **Verbatim request below:** the complete coordinator feedback request from the Phase 2 chat is reproduced unchanged. Additional instructions follow separately.

---

## Verbatim feedback request

I'd like Phase 1's coordinator to act as an **independent scientific reviewer of SIGMA's underlying research**, looking backward from the papers to identify what Investigator and Skeptic could have done better.

The most valuable feedback would concern these eight areas.

| Area | Questions for Phase 1's coordinator |
|---|---|
| **1. Missed research opportunities** | What important deductions, hypotheses, counterexamples, or lines of investigation were missed despite having enough information to pursue them? |
| **2. Skeptic effectiveness** | Did Skeptic challenge the strongest assumptions, find meaningful counterexamples, and force Investigator to improve its reasoning? Where was skepticism superficial? |
| **3. Research methodology** | Were the right scientific methods selected? What alternative experiments, mathematical techniques, causal analyses, or engineering evaluations should have been performed? |
| **4. Evidence quality** | Were important sources missing, unexamined, misinterpreted, or insufficiently validated? Did agents confuse their own reasoning with independently established evidence? |
| **5. Cross-strategy intelligence** | Did strategies genuinely benefit from one another's findings? Were contradictions, corrections, or useful deductions lost between rounds? |
| **6. Depth of reasoning** | Where did research stop at a plausible explanation instead of pursuing a rigorous derivation, discriminating experiment, or stronger conclusion? |
| **7. Scientific uncertainty** | Were claims overstated, assumptions left implicit, or hypothetical results treated as validated? Were legitimate findings unnecessarily weakened? |
| **8. Research completeness** | What unresolved obligations, partially developed proofs, failed reviews, or promising avenues should the agents have pursued further? |

## Three particularly important domain-specific questions

**AI Agent Reliability:** Did the agents go far enough in analyzing ambiguous external side effects, observation limits, exactly-once guarantees, failure histories, and statistical evaluation? What could have transformed the research from a useful conceptual framework into something more technically conclusive?

**Sovereign AI Federation:** Did the agents sufficiently explore architectural alternatives, economic counterexamples, policy enforcement, and fairness? What research could have resolved more of the outstanding questions rather than producing additional conditional proposals?

**Xenopus Tadpoles:** Did the agents adequately discriminate among competing biological explanations? Were there better experimental controls, causal-identification approaches, or analyses of existing biological data that could have sharpened the hypothesis?

## The most important distinction

I want the coordinator to identify **deficiencies in research, not deficiencies in writing**.

For example:

- "The paper omitted the redox alternative" is primarily Phase 1 feedback.
- "The investigators never tested whether the redox alternative could be distinguished from their preferred mechanism" is directly actionable Phase 2 feedback.

I would also appreciate identification of **exceptionally good research behaviors that we must preserve**. We're trying to advance a quality frontier, not replace one set of strengths with another.

## Ideal feedback format

For each significant finding, I'd like the coordinator to provide:

**Observed research behavior → Scientific weakness → Relevant source or methodology → Better Investigator/Skeptic behavior → Expected research-quality improvement.**

Include exact project, session, strategy, turn and evidence references wherever possible, plus whether the proposed improvement is generalizable across domains.

Most importantly, I'd like **several independent opportunities for improvement**, not just the single biggest weakness. That will let me design an iteration 2 that advances mathematical rigor, evidence discovery, skeptical depth, and experimental methodology simultaneously.

One final request: **ask Phase 1's coordinator to be ambitious scientifically.** I don't want the review limited to what SIGMA's present prompts make easy. I want to know what a capable human researcher would have pursued, why it mattered, and how close our existing Investigator/Skeptic system could get through better research methods without changing its architecture.

---

## Additional operational and scientific review directions

**Why this request exists.** Phase 1 ([PR #430](https://github.com/bkramerext/sigma/pull/430)) optimizes paper writing from **frozen existing research**; it must not alter the original research or confound the manuscript experiment. Phase 2 ([issue #432](https://github.com/bkramerext/sigma/issues/432), [PR #433](https://github.com/bkramerext/sigma/pull/433)) improves the **intellectual quality of Investigator/Skeptic session research**. Phase 2's Chat coordinator owns deep scientific judgment and Green executes full N-strategy, three-round, 12-total-role-turn sessions and engineering/bug reports. We want independent advice from Phase 1's coordinator, **not an assignment for Blue to implement Phase 2 changes**. Review the original saved research data, not only the manuscript. This request does not alter PR #430's active numbered mailbox, experiment freeze, or Blue's current iteration. No new research/provider calls are requested.

**Confirm research-versus-authoring causation.** For each alleged weakness, explicitly distinguish:
- (A) The session itself lacked a derivation, source inspection, falsification, objection uptake or resolution.
- (B) The research contained it, but paper planning/evidence indexing discarded or obscured it.
- (C) The research contains a plausible but *unverified* argument; neither absence nor proof can be asserted from the paper.
- (D) An execution integrity failure, such as inaccessible cited obligations or an incomplete last Skeptic review, that limits the trustworthiness or completeness of research.
- (E) Insufficient available source data to classify. Mark **UNVERIFIED** rather than guess.

**Source-of-truth audit.** Where accessible, inspect all strategies/rounds/roles, preserved session outputs, obligation manifests, contradictory or superseded findings, and exact original evidence spans. Cite project/session/strategy/turn/artifact IDs. Distinguish primary literature actually retrieved and inspected, uninspected URLs, hypothesized facts, model-internal derivations, independent computations and real empirical observations. Preserve explicit unresolved, partial, and failed review status. Do not imply repeated agent agreement establishes independent verification.

**Independently check the hard scientific content.** Re-derive pivotal numerical/theoretical results when possible; search for counterexamples, missing quantifiers, omitted assumptions, selection bias, alternative causal mechanisms, invalid transfer from illustrative cases, and statistical unit errors. When external material is needed, read specific relevant primary or methodological sections rather than relying solely on abstracts, snippets or search results. Useful reference families already identified for Phase 2 include NASEM's *Reproducibility and Replicability in Science*, the Cochrane Handbook (source search/bias/certainty, applied selectively), NIST/SEMATECH design of experiments, Hernán and Robins' *Causal Inference: What If*, the Stanford Encyclopedia of Philosophy on abduction, ACM SIGSOFT Empirical Standards, NIH/NC3Rs experimental rigor, NASA systems trade studies, and Center for Open Science guidance on exploratory versus confirmatory inference. Cite a precise source, section and why the method applies; avoid forcing clinical or animal-study checklists on purely mathematical proofs.

**Trace candidate interventions to the current system.** For each proposed Investigator or Skeptic improvement, state whether it can be achieved through bounded instruction/prompt changes, selective context/provenance handling, or minimally invasive research-content validation. **Do not propose** redesign of the Investigator/Skeptic loop, scheduler, concurrency, core architecture, UI, UX or paper generator. Do not prescribe new agents, default extra turns, live provider calls, or fabricated benchmarks. Existing cross-strategy sharing must continue.

**Balanced multi-frontier findings.** Cover *all three* test subjects and multiple dimensions: correctness, original reasoning depth, source quality, skeptic effectiveness, falsifiability/experiment design, cross-strategy learning, calibrated uncertainty, and actionable unresolved obligations. Include at least one positive research strength worth safeguarding in each subject, not merely failures. Separate P0 execution integrity fixes from scientific method improvements. Where a single issue dominates, still identify independently valuable work on other dimensions within the same iteration.

**Precise handoff artifact.** Commit a clearly named coordinator review in this PR's `docs/evaluations/report_quality/` area and link it in a PR comment. Suggested title: `PHASE2_ITERATION2_RESEARCH_ADVICE.md`. For each finding, use:
`Project / strategy / turn(s) / exact evidence → confirmed observation → research defect or demonstrated strength → methodological reference → suggested Investigator/Skeptic behavior → expected improvement → concrete regression/quality test → confidence and caveats`.
Then add a compact cross-subject matrix with **must-preserve strengths**, missed opportunities, generalizable interventions, and unresolved evidence-access questions. Distinguish scientific proposals from experimentally demonstrated improvements; Phase 2 Chat will independently adjudicate and prioritize. The handoff is input to Phase 2 **iteration 2**, not unilateral authorization to change Green's work or Phase 1 manuscripts.

**Timing and coordination.** Finish the active Phase 1 deep review without interrupting its in-flight run or rewriting numbered Blue messages. If its review has already identified more recent research-content findings, incorporate those rather than using stale I1/I2 observations. Commit this note and handoff through PR #430 only; no merge/deploy or autonomous downstream coordination.
